Literature DB >> 22283189

Characterization of cancer stem-like cells in chordoma.

Esra Aydemir1, Omer Faruk Bayrak, Fikrettin Sahin, Basar Atalay, Gamze Torun Kose, Mustafa Ozen, Serhat Sevli, Altay Burak Dalan, Mehmet Emir Yalvac, Turgut Dogruluk, Uğur Türe.   

Abstract

OBJECT: Chordomas are locally aggressive bone tumors known to arise from the remnants of the notochord. Because chordomas are rare, molecular studies aimed at developing new therapies are scarce and new approaches are needed. Chordoma cells and cancer stem-like cells share similar characteristics, including self-renewal, differentiation, and resistance to chemotherapy. Therefore, it seems possible that chordomas might contain a subpopulation of cancer stem-like cells. The aim of this study is to determine whether cancer stem-like cells might be present in chordomas.
METHODS: In this study, the authors used gene expression analysis for common cancer stem-like cellmarkers, including c-myc, SSEA-1, oct4, klf4, sox2, nanog, and brachyury, and compared chordoma cells and tissues with nucleus pulposus tissues (disc degenerated nontumorigenic tissues). Differentiation through agents such as all-trans retinoic acid and osteogenic differentiation medium was induced to the chordoma cells. Additionally, U-CH1 cells were sorted via magnetic cell sorting for stem cell markers CD133 and CD15. After separation, positive and negative cells for these markers were grown in a nonadherent environment, soft agar, to determine whether the presence of these cancer stem-like cells might be responsible for initiating chordoma. The results were compared with those of untreated cells in terms of migration, proliferation, and gene expression by using reverse transcriptase polymerase chain reaction.
RESULTS: The results indicate that chordoma cells might be differentiating and committing into an osteogenic lineage when induced with the osteogenic differentiation agent. Chordoma cells that are induced with retinoic acid showed slower migration and proliferation rates when compared with the untreated cells. Chordoma cells that were found to be enriched by cancer stem-like cell markers, namely CD133 and CD15, were able to live in a nonadherent soft agar medium, demonstrating a self-renewal capability. To the authors' knowledge, this is the first time that cancer stem-like cell markers were also found to be expressed in chordoma cells and tissues.
CONCLUSIONS: Cancer stem-like cell detection might be an important step in determining the recurrent and metastatic characteristics of chordoma. This finding may lead to the development of new approaches toward treatments of chordomas.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22283189     DOI: 10.3171/2011.12.JNS11430

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  21 in total

1.  Chordoma: an update on the pathophysiology and molecular mechanisms.

Authors:  Xin Sun; Francis Hornicek; Joseph H Schwab
Journal:  Curr Rev Musculoskelet Med       Date:  2015-12

Review 2.  An overview of the role of cancer stem cells in spine tumors with a special focus on chordoma.

Authors:  Mojdeh Safari; Alireza Khoshnevisan
Journal:  World J Stem Cells       Date:  2014-01-26       Impact factor: 5.326

3.  High-resolution whole-genome analysis of skull base chordomas implicates FHIT loss in chordoma pathogenesis.

Authors:  Roberto Jose Diaz; Mustafa Guduk; Rocco Romagnuolo; Christian A Smith; Paul Northcott; David Shih; Fitim Berisha; Adrienne Flanagan; David G Munoz; Michael D Cusimano; M Necmettin Pamir; James T Rutka
Journal:  Neoplasia       Date:  2012-09       Impact factor: 5.715

4.  Expression and Therapeutic Potential of SOX9 in Chordoma.

Authors:  Hua Chen; Cassandra C Garbutt; Dimitrios Spentzos; Edwin Choy; Francis J Hornicek; Zhenfeng Duan
Journal:  Clin Cancer Res       Date:  2017-06-12       Impact factor: 12.531

5.  UM-Chor1: establishment and characterization of the first validated clival chordoma cell line.

Authors:  John Henry Owen; Christine M Komarck; Anthony C Wang; Waleed M Abuzeid; Richard F Keep; Erin L McKean; Stephen Sullivan; Xing Fan; Mark E P Prince
Journal:  J Neurosurg       Date:  2017-04-21       Impact factor: 5.115

Review 6.  The molecular aspects of chordoma.

Authors:  Sukru Gulluoglu; Ozlem Turksoy; Aysegul Kuskucu; Ugur Ture; Omer Faruk Bayrak
Journal:  Neurosurg Rev       Date:  2015-09-12       Impact factor: 3.042

7.  MicroRNA expression profiling reveals the potential function of microRNA-31 in chordomas.

Authors:  Omer Faruk Bayrak; Sukru Gulluoglu; Esra Aydemir; Ugur Ture; Hasan Acar; Basar Atalay; Zeynel Demir; Serhat Sevli; Chad J Creighton; Michael Ittmann; Fikrettin Sahin; Mustafa Ozen
Journal:  J Neurooncol       Date:  2013-08-03       Impact factor: 4.130

8.  Chemotherapy of skull base chordoma tailored on responsiveness of patient-derived tumor cells to rapamycin.

Authors:  Lucia Ricci-Vitiani; Daniele Runci; Quintino Giorgio D'Alessandris; Tonia Cenci; Maurizio Martini; Federico Bianchi; Giulio Maira; Louis Stancato; Ruggero De Maria; Luigi Maria Larocca; Roberto Pallini
Journal:  Neoplasia       Date:  2013-07       Impact factor: 5.715

9.  Converging paths to progress for skull base chordoma: Review of current therapy and future molecular targets.

Authors:  Salvatore Di Maio; Esther Kong; Stephen Yip; Robert Rostomily
Journal:  Surg Neurol Int       Date:  2013-06-01

10.  The stemness phenotype model.

Authors:  M H Cruz; A Sidén; G M Calaf; Z M Delwar; J S Yakisich
Journal:  ISRN Oncol       Date:  2012-08-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.